Recurrent Ovarian Cancer Clinical Trial
Official title:
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
The purpose of this study is to evaluate the incidence rate and severity of pre-specified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer [PSOC] or platinum-resistant ovarian cancer [PROC]) with high folate receptor alpha (FRĪ±) expression.
Participants will be randomized (1:1) to 1 of 2 ocular adverse event (AE) risk mitigation strategy arms (primary prophylactic steroid eye drops versus primary prophylactic vasoconstricting eye drops). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02195973 -
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05270720 -
Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06070285 -
Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
|
||
| Completed |
NCT02303912 -
Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT01802749 -
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
|
Phase 3 | |
| Completed |
NCT02788708 -
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
|
Phase 1 | |
| Recruiting |
NCT03564340 -
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05610735 -
Combination Therapy for Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02083536 -
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
|
Phase 1 | |
| Completed |
NCT03430518 -
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
|
Phase 1 | |
| Recruiting |
NCT03618706 -
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT05311579 -
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01851746 -
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
|
N/A | |
| Active, not recruiting |
NCT06107868 -
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
|
Phase 1 | |
| Recruiting |
NCT06308406 -
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04718740 -
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05335993 -
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
|
Phase 2 | |
| Completed |
NCT01381861 -
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05126342 -
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
|
Phase 2 | |
| Completed |
NCT02849353 -
Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer
|
Phase 1/Phase 2 |